首页> 美国卫生研究院文献>Oncotarget >Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells
【2h】

Androgen suppresses protein kinase D1 expression through fibroblast growth factor receptor substrate 2 in prostate cancer cells

机译:雄激素通过前列腺癌细胞中的成纤维细胞生长因子受体底物2抑制蛋白激酶D1表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In prostate cancer, androgen/androgen receptor (AR) and their downstream targets play key roles in all stages of disease progression. The protein kinase D (PKD) family, particularly PKD1, has been implicated in prostate cancer biology. Here, we examined the cross-regulation of PKD1 by androgen signaling in prostate cancer cells. Our data showed that the transcription of PKD1 was repressed by androgen in androgen-sensitive prostate cancer cells. Steroid depletion caused up regulation of PKD1 transcript and protein, an effect that was reversed by the AR agonist R1881 in a time- and concentration-dependent manner, thus identifying PKD1 as a novel androgen-repressed gene. Kinetic analysis indicated that the repression of PKD1 by androgen required the induction of a repressor protein. Furthermore, inhibition or knockdown of AR reversed AR agonist-induced PKD1 repression, indicating that AR was required for the suppression of PKD1 expression by androgen. Downstream of AR, we identified fibroblast growth factor receptor substrate 2 (FRS2) and its downstream MEK/ERK pathway as mediators of androgen-induced PKD1 repression. In summary, PKD1 was identified as a novel androgen-suppressed gene and could be downregulated by androgen through a novel AR/FRS2/MEK/ERK pathway. The upregulation of prosurvival PKD1 by anti-androgens may contribute to therapeutic resistance in prostate cancer treatment.
机译:在前列腺癌中,雄激素/雄激素受体(AR)及其下游靶标在疾病进展的所有阶段均发挥关键作用。蛋白激酶D(PKD)家族,特别是PKD1,已与前列腺癌生物学有关。在这里,我们检查了前列腺癌细胞中雄激素信号传导对PKD1的交叉调节。我们的数据表明,雄激素敏感性前列腺癌细胞中雄激素抑制了PKD1的转录。类固醇的耗竭引起了PKD1转录物和蛋白质的上调,AR激动剂R1881以时间和浓度依赖性的方式逆转了这种作用,从而将PKD1鉴定为一种新的雄激素抑制基因。动力学分析表明,雄激素抑制PKD1需要诱导阻遏蛋白。而且,AR的抑制或敲低逆转了AR激动剂诱导的PKD1阻遏,表明AR是雄激素抑制PKD1表达所必需的。在AR的下游,我们确定了成纤维细胞生长因子受体底物2(FRS2)及其下游的MEK / ERK途径是雄激素诱导的PKD1抑制的介质。总之,PKD1被鉴定为一种新的雄激素抑制基因,并可能通过新的AR / FRS2 / MEK / ERK途径被雄激素下调。抗雄激素上调生存前PKD1可能有助于前列腺癌治疗中的治疗耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号